GLP-1 Medication vs Bariatric Surgery

Breakfast, fried egg, table, table setting, food, morning, meal, healthy, protein, brunch, toast, breakfast, breakfast, breakfast, breakfast, breakfast, fried egg, fried egg, food, food, morning, prot

GLP-1 medication vs bariatric surgery: average weight loss, how long it lasts, risks, combining both, two-year costs and coverage, from labels, guidelines and major studies.

By marketing Updated October 7, 2026 Facts checked October 6, 2026

Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.

Key takeaways

  • No randomized trial has compared today's GLP-1 medicines directly with bariatric surgery as of 2026-10-06.[1]
  • In a 2025 U.S. cohort of 30,458 adults with a BMI of 35 or more, average total weight loss was 28.3% after surgery and 10.3% with GLP-1 medicines as used in practice.[1]
  • In the main trials, GLP-1 medicines led to about 15% (semaglutide 2.4 mg) to 21% (tirzepatide 15 mg) average weight loss.[3]
  • Weight tends to return after GLP-1 medicines stop: in SURMOUNT-4, people switched to placebo regained 14.0% over a year.[5]
  • Surgery carries a risk of death of about 0.1% and of major complications of about 4%, plus lifelong vitamin needs.[15]

The short answer

GLP-1 medicines and bariatric surgery both treat obesity. On average surgery has led to larger, longer-lasting weight loss (about 25% to 31% at one year) than the main GLP-1 trials (about 15% to 21%), but it carries surgical risks and lifelong vitamin needs. Medicines avoid surgery but are usually taken long term, and weight tends to return when they stop. There is no randomized head-to-head trial; many people use both at different times.

Scorecards

Semaglutide: one ingredient, several brandsFDA approved for weight managementPrescriptionInjectionGastric Sleeve Surgery: eligibility, results, risks and costSurgical
Evidence—High
Invasiveness—Surgical
Medical supervision—Required
Cost—$$$$
Maintenance—Ongoing

No overall score and no winner: what matters depends on you. Hover a value for its definition.

Facts side by side

Semaglutide: one ingredient, several brandsFDA approved for weight managementPrescriptionInjectionGastric Sleeve Surgery: eligibility, results, risks and costSurgical
PurposeChronic weight management (Wegovy); Glycemic control in type 2 diabetes (Ozempic)Medical weight loss
Class or typeGLP-1 receptor agonistBariatric surgery
Regulatory statusFDA approved for weight managementPrescriptionInjectionSurgical
Prescription requiredYesPerformed by a clinician
How it worksSemaglutide across its brands (Wegovy, Ozempic, Rybelsus): how it works, approved uses, STEP, SELECT and OASIS results, side effects and compounded versions.About 80% of the stomach is stapled and removed, leaving a banana-shaped tube. A smaller stomach fills sooner, and the operation changes gut hormones that affect hunger, fullness and blood sugar. The intestines are not rerouted.
How it is done or takenInjectionSurgical
How oftenDaily, WeeklyOne-time
Invasiveness—Surgical
Evidence strength—High
Average outcomes in studies
  • STEP 1: -14.9% vs -2.4% body weight (semaglutide 2.4 mg weekly vs placebo).
  • OASIS 4: -13.6% vs -2.2% body weight (oral semaglutide 25 mg daily vs placebo).
  • Average total weight loss 25.2% at 1 year and 18.8% at 5 years (PCORnet, 29,693 sleeve patients). Excess weight loss 49% at 5 years and 43.5% (median) at 10 years in the SLEEVEPASS trial; excess BMI loss 61.1% at 5 years in SM-BOSS.
Main risks
  • Thyroid C-cell tumors (boxed warning, rodents)
  • Acute pancreatitis
  • Acute gallbladder disease
  • Major adverse events within 30 days: 2.6% (PCORnet)
  • Bleeding, infection, staple-line leak, blood clots and, rarely, death (NIDDK)
  • New or worse reflux: worsened in 31.8% at 5 years in SM-BOSS; esophagitis 31% at 10 years in SLEEVEPASS
Downtime—2+ weeks
Cost (dated)—from 17,000-26,000 USD average cost range for bariatric surgery overall (ASMBS; not sleeve-specific) (checked October 6, 2026)
$$$$
Insurance—Often covered
Maintenance—Ongoing
Advantages—
  • Technically simpler and shorter than bypass operations (ASMBS)
  • Fewer major adverse events in the first 30 days than bypass (2.6% vs 5.0%, PCORnet)
  • No intestinal rerouting, so fewer absorption problems than bypass or duodenal switch
Limitations—
  • Cannot be reversed: most of the stomach is removed
  • May cause or worsen reflux and esophagitis
  • Somewhat less weight loss and metabolic effect than a bypass on average
Who performs or prescribes it—Bariatric surgery
Official resourcesdailymed.nlm.nih.govcms.gov

What the trials showed

  • No randomized head-to-head trial found; observational comparison (Barrett 2025) 30,458 adults with BMI 35+ in a U.S. insurance cohort: total weight loss 28.3% after sleeve or bypass vs 10.3% with GLP-1 medicines (patients with weight data); 2-year total costs $51,794 vs $63,483.[1]

Side effects compared

Semaglutide: one ingredient, several brandsFDA approved for weight managementPrescriptionInjectionGastric Sleeve Surgery: eligibility, results, risks and costSurgical
From the label
  • Nausea (44% vs 16% (Wegovy 2.4 mg); 15.8% to 20.3% vs 6.1% (Ozempic 0.5 to 1 mg))
  • Diarrhea (30% vs 16% (Wegovy); 8.5% to 8.8% vs 1.9% (Ozempic))
  • Vomiting (24% vs 6% (Wegovy); 5.0% to 9.2% vs 2.3% (Ozempic))
  • Constipation (24% vs 11% (Wegovy); 3.1% to 5.0% vs 1.5% (Ozempic))
  • Major adverse events within 30 days: 2.6% (PCORnet)
  • Bleeding, infection, staple-line leak, blood clots and, rarely, death (NIDDK)
  • New or worse reflux: worsened in 31.8% at 5 years in SM-BOSS; esophagitis 31% at 10 years in SLEEVEPASS
  • Barrett's esophagus: 4% at 10 years in SLEEVEPASS
  • Narrowing of the sleeve (stricture), hernias and gallstones after rapid weight loss
  • Vitamin and mineral deficiencies: B12 4-20%, iron under 18%, zinc 19% (ASMBS 2016)

Cost and coverage

OptionPriceAmountBasisChecked on
Gastric Sleeve Surgery: eligibility, results, risks and costTypical total (national data)17,000-26,000 USDaverage cost range for bariatric surgery overall (ASMBS; not sleeve-specific)October 6, 2026

Prices change often and depend on pharmacy, plan and location. Insurance can change what you pay. Every price shows the date we checked it.

Things people weigh up

  • Average weight loss: larger with surgery in observational comparisons; GLP-1 trial averages ranged from about 15% to 21%.
  • Durability: surgery's effect is built in; GLP-1 effects usually fade after stopping.
  • Risks: surgery has operative risks and lifelong supplement needs; medicines have mostly digestive side effects plus class warnings.
  • Commitment: surgery means a one-time operation and lifelong follow-up; medicines mean ongoing prescriptions, monthly costs and check-ins.
  • Eligibility: medicine labels start at BMI 30 (27 with a condition); surgery guidelines start at BMI 35 (30 with metabolic disease).
  • Cost: in two U.S. studies, two-year total costs were lower after surgery than with GLP-1 medicines; individual costs depend on coverage.
  • They can be combined: medicine before or after surgery is common; timing is a team decision.

These are the differences people commonly consider, not a recommendation. A clinician can help you decide what fits you.

In short: GLP-1 medicines (such as Wegovy and Zepbound) and metabolic and bariatric surgery (mainly the sleeve and the gastric bypass) are both treatments for obesity that work partly through the same gut-hormone pathways. On average, surgery has led to larger and longer-lasting weight loss: about 25% to 31% of body weight at one year in a large U.S. study, versus about 15% to 21% in the main GLP-1 medicine trials. Surgery is a one-time operation with surgical risks and lifelong vitamin needs; GLP-1 medicines avoid surgery but are usually taken long term, and weight tends to return when they stop. No randomized trial has compared today’s GLP-1 medicines directly with surgery (checked on October 6, 2026). Many people use both at different times.

This is one of the biggest decisions in weight care, and it is personal. This page gathers the facts from FDA labels, guidelines and the best available studies so you can research and ask better questions. It is not a recommendation: please talk with a licensed doctor, ideally both an obesity-medicine clinician and a bariatric surgeon, and complete a full evaluation before choosing either path.

Medication vs surgery at a glance

  • 28.3% vs 10.3%average total weight loss with surgery vs GLP-1 medicines in a U.S. insurance cohort (30,458 people with BMI 35+)JAMA Surgery 2025
  • $51,794 vs $63,483average total health care costs over 2 years, surgery vs GLP-1 medicines (same cohort)JAMA Surgery 2025
  • About 1%share of people eligible for bariatric surgery who have itASMBS

Checked on October 6, 2026

The two paths side by side

GLP-1 medicines (guide)Bariatric surgery (guide)
Main optionsWegovy (semaglutide), Zepbound (tirzepatide), Saxenda, and the pills Wegovy pill and FoundayoGastric sleeve, gastric bypass; less often duodenal switch and others
What it isPrescription medicine, weekly injection or daily pillOperation, usually laparoscopic under general anesthesia; mostly permanent
Who it is labeled or recommended forLabels: adults with obesity, or overweight with a weight-related condition (some also teens)2022 ASMBS/IFSO guidelines: BMI of 35 or more; considered from 30 to 34.9 with metabolic disease (lower thresholds for people of Asian descent)
Average weight lossAbout 15% (semaglutide 2.4 mg, STEP 1) to 21% (tirzepatide 15 mg, SURMOUNT-1) in trialsAbout 25% (sleeve) to 31% (bypass) at 1 year; 19% to 26% at 5 years (PCORnet)
How long it lastsWeight tends to return after stopping; usually taken long termMost weight loss is maintained for years, with some regain
Main risksDigestive side effects; thyroid C-cell tumor boxed warning; pancreatitis; gallbladder diseaseSurgical complications (death about 0.1%, major complications about 4%); lifelong vitamin and mineral needs; reflux (sleeve); ulcers and dumping (bypass)
Who provides itAny licensed prescriber; often primary care or obesity medicineA bariatric surgeon and team, ideally at an accredited center
Cost patternMonthly, ongoingMostly up front, then follow-up and supplements
Sources: FDA labels (DailyMed); Eisenberg D et al., SOARD 2022; Arterburn D et al., Ann Intern Med 2018; ASMBS. Checked on October 6, 2026.

How each one works

GLP-1 is a hormone the gut releases after meals; it signals fullness and slows stomach emptying. GLP-1 medicines copy it (tirzepatide also copies a second hormone, GIP), which lowers appetite while the medicine is taken. Bariatric surgery shrinks the stomach and, with the bypass, reroutes the intestine; studies show both operations also raise the body’s own after-meal GLP-1 levels, which is thought to be one reason they affect hunger and blood sugar so strongly. The effect of surgery is built in, while the effect of a medicine lasts only as long as it is taken.

What the evidence shows on weight

No head-to-head trial yet. As of October 6, 2026, we found no randomized trial comparing today’s GLP-1 medicines with surgery. The evidence comes from each treatment’s own studies and from observational comparisons, which can be affected by who chose which treatment.

Average weight lost in key studies of each approachValues in %
Average weight lost in key studies of each approach
ItemValue
Gastric bypass, 1 year (PCORnet)31.2%
Gastric sleeve, 1 year (PCORnet)25.2%
Tirzepatide 15 mg, 72 weeks (SURMOUNT-1)20.9%
Semaglutide 2.4 mg, 68 weeks (STEP 1)14.9%
Gastric bypass, 5 years (PCORnet)25.5%
Gastric sleeve, 5 years (PCORnet)18.8%

Different study types and populations: surgical patients had higher starting BMIs (35+). Not a head-to-head comparison.

Source: Arterburn D et al., Ann Intern Med 2018 (PCORnet, observational); Jastreboff AM et al., NEJM 2022; Wilding JPH et al., NEJM 2021 (checked on October 6, 2026)

A real-world comparison. A 2025 JAMA Surgery study used insurance claims and health records from Highmark Health and the Allegheny Health Network for 30,458 adults with class II or III obesity (BMI 35 or more): 14,101 had a sleeve or bypass and 16,357 started a GLP-1 medicine. After statistical matching, average total weight loss was 28.3% with surgery and 10.3% with GLP-1 medicines, based on the patients with weight data (1,291 and 257). The GLP-1 group included older, less potent medicines and people who stopped them, which likely lowered its average; the authors call for more study.

Average total weight loss in a real-world U.S. comparison (BMI 35+)Values in %
Average total weight loss in a real-world U.S. comparison (BMI 35+)
ItemValue
Bariatric surgery (sleeve or bypass)28.3%
GLP-1 medicines (all types, as used)10.3%

Observational, propensity-weighted; GLP-1 group included dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide and tirzepatide, and real-world stopping.

Source: Barrett TS et al., JAMA Surgery 2025 (Highmark/Allegheny cohort) (checked on October 6, 2026)

How long results last. After surgery, the Swedish Obese Subjects study found the bypass group’s weight loss peaked at 32% at 1 to 2 years and stabilized at 25% after 10 years. In the U.S. LABS-2 study, people were 28.4% lighter 7 years after a bypass, with an average regain of 3.9% between years 3 and 7. With medicines, stopping usually brings weight back: in SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% over a year, while those who continued lost a further 5.5%; in STEP 4, a switch from semaglutide to placebo led to a 6.9% regain over 48 weeks.

What happened when GLP-1 treatment continued or stoppedValues in %
What happened when GLP-1 treatment continued or stopped
ItemContinued (further loss)Switched to placebo (regain)
Tirzepatide (SURMOUNT-4, weeks 36-88)5.5%14%
Semaglutide (STEP 4, weeks 20-68)7.9%6.9%

First bar of each pair = additional weight lost by people who kept taking the medicine; second = weight regained after switching to placebo.

Source: Aronne LJ et al., JAMA 2024 (SURMOUNT-4); Rubino D et al., JAMA 2021 (STEP 4) (checked on October 6, 2026)

Diabetes, heart and other health outcomes

  • Type 2 diabetes after surgery: in LABS-2, 71.2% of people with diabetes were in remission 1 year after bypass and 60.2% at 7 years. In the STAMPEDE trial, 29% (bypass) and 23% (sleeve) reached an HbA1c of 6.0% or less at 5 years, versus 5% with intensive medical therapy, which did not include today’s GLP-1 obesity doses.
  • Heart outcomes with a GLP-1: in SELECT, semaglutide 2.4 mg lowered major cardiovascular events (6.5% vs 8.0% with placebo) in adults with heart disease and overweight or obesity, the basis of Wegovy’s heart-risk approval.
  • Survival after surgery: in the Swedish Obese Subjects study, the adjusted risk of death over about 11 years was 29% lower with surgery than with usual care (hazard ratio 0.71); this was not a randomized trial.
  • Sleep apnea: Zepbound is FDA approved for moderate to severe obstructive sleep apnea in adults with obesity; surgery also improves sleep apnea in many people.

Risks compared

GLP-1 medicinesBariatric surgery
Common problemsNausea (44% with Wegovy 2.4 mg, 25% to 29% with Zepbound vs 8% to 16% on placebo), diarrhea, vomiting, constipation, mostly earlyPain and recovery after an operation; food intolerance during diet stages; dumping (more after bypass); reflux (more after sleeve)
Serious risksPancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar with insulin or sulfonylureas, aspiration during anesthesia; boxed warning for thyroid C-cell tumors seen in rodentsBleeding, infection, leaks, blood clots; death about 0.1% and major complications about 4% overall; 30-day major adverse events 2.6% (sleeve) to 5.0% (bypass) in PCORnet
Long termUsually taken long term with monthly costs; weight regain on stoppingLifelong vitamins and blood tests; anemia and bone loss risk; about one-third need a follow-up procedure, surgery or hospital stay within 5 years (NIDDK)
PregnancyWegovy: stop when pregnancy is recognized; Ozempic’s label advises stopping 2 months before a planned pregnancyPregnancy usually advised against for 12 to 18 months after surgery
Sources: Wegovy and Zepbound prescribing information; ASMBS; NIDDK; Arterburn D et al., 2018; AACE/TOS/ASMBS 2019 guideline. Checked on October 6, 2026.

Using both: before or after surgery

Medication and surgery are not always either-or. Some people take a GLP-1 medicine first and consider surgery later, and some start one after surgery if weight returns or loss is not enough. A 2024 review of 19 studies of GLP-1 medicines after bariatric surgery found average additional losses of about 7 kg (15 lb) with liraglutide and greater losses with weekly semaglutide, with nausea in about 19% of people. These were mostly observational studies at lower doses than today’s obesity doses. Timing and safety are decisions for your surgical team and prescriber.

Cost and coverage (checked on October 6, 2026)

Surgery costs most up front; medicines cost every month. Two U.S. studies compared total health care spending over two years:

Total health care costs over 2 years in two U.S. studies
Total health care costs over 2 years in two U.S. studies
ItemGLP-1 medicinesSurgery
Highmark cohort, BMI 35+ (surgery = sleeve or bypass)$63,483$51,794
ASMBS 2026 study, type 2 diabetes + BMI 35+ (surgery = sleeve)$58,600$41,400
ASMBS 2026 study, type 2 diabetes + BMI 35+ (surgery = bypass)$58,600$51,300

Totals include medicines, the operation and other medical care. Based on claims from earlier years, before today's self-pay prices; the ASMBS study is a conference presentation, not yet peer reviewed.

Source: Barrett TS et al., JAMA Surgery 2025; ASMBS news release, May 5, 2026 (conference presentation, STATinMED claims 2017-2023) (checked on October 6, 2026)

  • Today’s prices: the ASMBS puts the average cost of bariatric surgery at $17,000 to $26,000. GLP-1 self-pay prices from the makers were $349 a month for most Wegovy pen strengths and $299 to $449 for Zepbound KwikPens or vials with on-time refills on 2026-10-06; see Wegovy cost and Zepbound cost.
  • Medicare: covers bariatric surgery for people with a BMI of 35 or more, at least one obesity-related condition and prior unsuccessful medical treatment (NCD 100.1). For medicines, the temporary GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy, Zepbound KwikPen and Foundayo for weight management with a $50 copay for people who meet its criteria.
  • Employer plans: in KFF’s 2025 survey, 43% of firms with 5,000 or more workers covered GLP-1s for weight loss; surgery coverage and criteria vary by plan. See GLP-1 insurance coverage and the insurance hub.

How people research this decision

Researching medication vs surgery

  1. Know your numbersCheck your BMI and list conditions such as diabetes, sleep apnea, heart disease or reflux.
  2. Learn both pathsRead the medication and procedure pages, including risks and the long-term commitment of each.
  3. See an obesity-medicine clinicianAsk about medicines, expected results for someone like you and what happens if you stop.
  4. Meet a bariatric teamAsk about the operation that might fit, center outcomes and the evaluation process.
  5. Check coverageAsk your plan what it covers for each and what prior authorization requires.
  6. Decide with your cliniciansThere is no single right answer; many people use both at different times.

Related pages: gastric sleeve vs gastric bypass, Wegovy vs Zepbound, life after a GLP-1, muscle loss on GLP-1s, and providers in obesity medicine and bariatric surgery. Find My Options can also help you see which categories to research.

Compared with the items

FDA approved for weight managementPrescriptionInjectionSemaglutide: one ingredient, several brandsInjection · Daily, WeeklySurgicalGastric Sleeve Surgery: eligibility, results, risks and costSurgical · 2+ weeks

Related comparisons

Semaglutide vs Tirzepatide: how the two molecules compareMedicationsGastric Sleeve vs Gastric BypassProcedures

Related guides

Bariatric Surgery: types, eligibility and life afterBariatric surgery explained: sleeve, bypass, duodenal switch and band compared, the 2022 eligibility guidelines, results, risks,…GLP-1 Medications: how they work and which are approved for weightGLP-1 medications explained: what GLP-1 is, how the drugs work, which brands are FDA approved for…Stopping a GLP-1: regain, what trials show and keeping resultsWhat happens when you stop a GLP-1: STEP 1 extension, STEP 4, SURMOUNT-4 and BMJ meta-analysis…

Tools for this topic

BMI Calculator for Adults (and what BMI cannot tell you)Free BMI calculator for adults with CDC categories, plus what BMI cannot tell you, why waist…

Questions to ask a professional

  • Based on my health, what results could I realistically expect from medication and from surgery?
  • What risks matter most for me with each path?
  • If I start with a medicine, at what point would we talk about surgery, and vice versa?
  • What happens if I stop the medicine, or if weight returns after surgery?
  • What will my insurance cover for each, and what does prior authorization require?
  • Which specialists should I see, and is your surgical center accredited?

Frequently asked questions

Is surgery more effective than GLP-1 medicines?

On average, surgery has led to more weight loss: about 25% to 31% at one year after sleeve or bypass in a large U.S. study, compared with about 15% to 21% in the main GLP-1 trials. There is no randomized head-to-head trial, and individual results vary.

Can a GLP-1 medicine replace bariatric surgery?

For some people the results may be enough; for others, surgery leads to more weight loss. The 2025 JAMA Surgery authors say more study is needed. This is a decision for you and your clinicians.

Do I have to take a GLP-1 forever?

The labels describe chronic (long-term) use, and trials show weight tends to return after stopping. Whether and how to stop is a plan to make with your prescriber.

Can I take a GLP-1 after bariatric surgery?

Yes, it is sometimes used when weight returns or loss is not enough. A 2024 review found extra losses of about 7 kg with liraglutide and more with semaglutide. Your surgical team and prescriber decide timing and safety.

Should I stop my GLP-1 before surgery?

GLP-1 labels warn about aspiration during anesthesia or deep sedation. Tell your surgeon and anesthesia team you take one, well before any procedure, and follow their instructions.

Which is cheaper over time?

In two U.S. studies, total two-year health care costs were lower after surgery ($41,400 to $51,794) than with GLP-1 medicines ($58,600 to $63,483). These used claims from earlier years, before current self-pay prices; your costs depend on coverage.

Who qualifies to be evaluated for surgery?

The 2022 ASMBS/IFSO guidelines recommend surgery for a BMI of 35 or more and say it can be considered from 30 to 34.9 with metabolic disease, with lower thresholds for people of Asian descent. A bariatric team decides after an evaluation.

Does Medicare cover either?

Medicare covers bariatric surgery for people with a BMI of 35 or more, a related condition and prior unsuccessful medical treatment. The temporary GLP-1 Bridge (July 2026 to December 2027) covers some GLP-1 medicines for weight with a $50 copay for people who meet its criteria.

References

  1. Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surgery, 2025. PMID 40960852 (accessed October 6, 2026) Other
  2. Arterburn D, et al.. Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study. Annals of Internal Medicine, 2018. doi:10.7326/M17-2786 · PMID 30383139 · NCT02741674 (accessed October 6, 2026) Other
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. doi:10.1056/NEJMoa2206038 · PMID 35658024 · NCT04184622 (accessed October 7, 2026) Randomized trial
  4. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
  5. Aronne LJ, Sattar N, Horn DB, et al.. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. doi:10.1001/jama.2023.24945 · PMID 38078870 · NCT04660643 (accessed October 7, 2026) Randomized trial
  6. Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021. doi:10.1001/jama.2021.3224 · PMID 33755728 · NCT03548987 (accessed October 7, 2026) Randomized trial
  7. Sjöström L, Narbro K, Sjöström CD, et al.. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects. New England Journal of Medicine, 2007. doi:10.1056/NEJMoa066254 · PMID 17715408 (accessed October 6, 2026) Other
  8. Courcoulas AP, et al.. Seven-Year Weight Trajectories and Health Outcomes in the LABS Study. JAMA Surgery, 2018. doi:10.1001/jamasurg.2017.5025 · PMID 29214306 · NCT00465829 (accessed October 6, 2026) Other
  9. Schauer PR, et al.. Bariatric Surgery versus Intensive Medical Therapy for Diabetes: 5-Year Outcomes (STAMPEDE). New England Journal of Medicine, 2017. doi:10.1056/NEJMoa1600869 · PMID 28199805 · NCT00432809 (accessed October 6, 2026) Randomized trial
  10. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 2023. doi:10.1056/NEJMoa2307563 · PMID 37952131 · NCT03574597 (accessed October 7, 2026) Randomized trial
  11. Çalık Başaran N, Dotan I, Dicker D. Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels. International Journal of Obesity, 2025. PMID 38225284 (accessed October 6, 2026) Review
  12. Esparham A, Mehri A, Dalili A, Richards J, Khorgami Z. Safety and efficacy of GLP-1 receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: a systematic review and meta-analysis. Obesity Reviews, 2024. PMID 39134066 (accessed October 6, 2026) Meta-analysis
  13. Eisenberg D, Shikora SA, Aarts E, et al.. 2022 ASMBS and IFSO: Indications for Metabolic and Bariatric Surgery. Surgery for Obesity and Related Diseases, 2022. doi:10.1016/j.soard.2022.08.013 · PMID 36280539 (accessed October 6, 2026) Guideline
  14. 2025 Fact Sheet: Metabolic and Bariatric Surgery (incl. SADI and OAGB counts). American Society for Metabolic and Bariatric Surgery, 2025. (accessed October 7, 2026) Society statement
  15. Metabolic and Bariatric Surgery (fact page, incl. average cost). American Society for Metabolic and Bariatric Surgery. (accessed October 6, 2026) Society statement
  16. Study Finds Bariatric Surgery Less Costly Than GLP-1 Drugs Over Time (news release). American Society for Metabolic and Bariatric Surgery, 2026. (accessed October 6, 2026) News (reported facts only)
  17. Side Effects of Weight-loss Surgery. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). (accessed October 6, 2026) Government page
  18. WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
  19. ZEPBOUND (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
  20. OZEMPIC (semaglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
  21. Mechanick JI, Apovian C, Brethauer S, et al.. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures: 2019 Update (AACE/TOS/ASMBS/OMA/ASA). Endocrine Practice, 2019. doi:10.4158/GL-2019-0406 · PMID 31682518 (accessed October 6, 2026) Guideline
  22. National Coverage Determination 100.1: Bariatric Surgery. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
  23. Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
  24. 2025 Employer Health Benefits Survey. KFF, 2025. (accessed October 6, 2026) Other
  25. Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
  26. Zepbound coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other

Facts checked on October 6, 2026

Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.